| In millions, except per share items | Oct-31-21 | Oct-31-20 | Oct-31-19 | Oct-31-18 | Oct-31-17 | Oct-31-16 | Oct-31-15 | Oct-31-14 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Patient Referrals and Product Sales | | | | | 0.6 | 0.2 | | |
| Total revenues | 5.6 | 3.1 | 0.1 | 1.0 | 0.6 | 0.2 | 0.1 | 0.0 |
| Revenue growth [+] | 83.2% | 4164.9% | -92.6% | 69.3% | 208.2% | 25.2% | | -100.0% |
| Patient Referrals and Product Sales | | | | | 208.2% | | | |
| Cost of goods sold | 0.5 | 0.4 | 0.3 | 0.2 | 0.2 | 0.1 | 0.0 | 0.0 |
| Gross profit | 5.0 | 2.7 | -0.2 | 0.8 | 0.4 | 0.1 | 0.1 | 0.0 |
| Gross margin | 90.2% | 87.0% | -319.9% | 78.3% | 71.8% | 48.9% | 66.5% | |
| Selling, general and administrative [+] | 17.8 | 15.1 | 3.2 | 4.2 | 9.1 | 1.1 | 0.8 | 0.1 |
| General and administrative [+] | 17.8 | 15.1 | 3.2 | 4.2 | 9.1 | 1.1 | 0.8 | 0.1 |
| General and administrative expenses | 17.8 | 15.1 | 3.2 | 4.2 | 9.1 | 1.1 | 0.8 | 0.1 |
| Other operating expenses | | | -1.6 | | | | | -0.1 |
| EBITDA [+] | -12.7 | -12.4 | -1.8 | -3.5 | -8.6 | -1.0 | -0.7 | |
| EBITDA growth | 2.3% | 603.9% | -49.4% | -59.6% | 726.7% | 40.1% | | -100.0% |
| EBITDA margin | -226.7% | -405.8% | -2458.8% | -361.0% | -1513.1% | -564.1% | -504.1% | |
| Depreciation and amortization | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| EBIT [+] | -12.7 | -12.4 | -1.8 | -3.5 | -8.6 | -1.0 | -0.7 | 0.0 |
| EBIT growth | 2.5% | 600.1% | -49.1% | -59.6% | 728.3% | 40.2% | | -100.0% |
| EBIT margin | -227.7% | -407.0% | -2479.4% | -361.8% | -1516.5% | -564.3% | -504.2% | |
| Interest expense | 0.0 | 0.2 | 0.0 | 0.2 | 0.6 | 0.0 | | |
| Interest expense | 0.0 | 0.2 | 0.0 | 0.2 | 0.6 | 0.0 | | |
| Other income (expense), net [+] | 0.0 | 0.0 | 0.1 | 0.3 | 0.1 | -0.2 | | -0.1 |
| Gain (loss) on derivative instruments | | | | 0.3 | 0.1 | | | |
| Other | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | | | |
| Pre-tax income | -12.8 | -12.6 | -1.7 | -3.4 | -9.1 | -1.3 | -0.7 | -0.1 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.8% | 30.7% |
| Minority interest | | | 0.0 | 0.0 | -0.1 | | | |
| Earnings from continuing ops | -12.8 | -12.6 | -1.7 | -3.5 | -9.0 | -1.1 | -0.7 | -0.1 |
| Earnings from discontinued ops | | | | | | -0.2 | 0.0 | 0.0 |
| Net income | -12.8 | -12.6 | -1.7 | -3.5 | -9.0 | -1.3 | -0.7 | -0.1 |
| Net margin | -227.9% | -411.8% | -2424.7% | -358.9% | -1574.5% | -677.8% | -500.1% | |
| |
| Basic EPS [+] | ($0.01) | ($0.02) | $0.00 | ($0.01) | ($0.08) | ($0.01) | ($0.01) | $0.00 |
| Growth | -35.8% | 404.2% | -70.8% | -84.6% | 685.3% | 89.5% | 777.8% | -84.3% |
| Diluted EPS [+] | ($0.01) | ($0.02) | $0.00 | ($0.01) | ($0.08) | ($0.01) | ($0.01) | $0.00 |
| Growth | -35.8% | 404.2% | -70.8% | -84.6% | 685.3% | 89.5% | 777.8% | -84.3% |
| |
| Shares outstanding (basic) [+] | 1,059.5 | 670.8 | 467.0 | 271.8 | 108.6 | 100.4 | 134.0 | 150.1 |
| Growth | 57.9% | 43.6% | 71.8% | 150.3% | 8.2% | -25.1% | -10.7% | 1783.7% |
| Shares outstanding (diluted) [+] | 1,059.5 | 670.8 | 467.0 | 271.8 | 108.6 | 100.4 | 134.0 | 150.1 |
| Growth | 57.9% | 43.6% | 71.8% | 150.3% | 8.2% | -25.1% | -10.7% | 1783.7% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |